{"id":389773,"date":"2022-09-26T00:00:00","date_gmt":"2022-09-26T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/concon0014-2022-biopharma-ovarian-cancer-china-in-depth-china-2022\/"},"modified":"2026-04-27T23:30:55","modified_gmt":"2026-04-27T23:30:55","slug":"concon0014-2022-biopharma-ovarian-cancer-china-in-depth-china-2022","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/concon0014-2022-biopharma-ovarian-cancer-china-in-depth-china-2022\/","title":{"rendered":"Ovarian Cancer | China In-Depth | China | 2022"},"content":{"rendered":"<p>The ovarian cancer market in China is poised to experience substantial market growth over the 2021-2031 forecast period. For patients with ovarian cancer, chemotherapy regimens remain the go-to option in the first-line setting. The recent approval and launch of PARP inhibitors\u2014Jiangsu HengRui\u2019s fluzoparib and BeiGene\u2019s pamiparib\u2014for later-line treatment has bolstered the treatment armamentarium for metastatic patients. The key driver of market growth will be the anticipated launch and uptake of several targeted therapies for ovarian cancer in China\u2014particularly from PARP inhibitors and immune checkpoint inhibitors\u2014and the incorporation of many of these therapies into China\u2019s National Reimbursement Drug List (NRDL), thereby securing better patient access. Additionally, following the recent reforms in China\u2019s regulatory and reimbursement landscape, manufacturers\u2014both domestic and multinational\u2014will be increasingly incentivized to enter the growing ovarian cancer market.<\/p>\n<p><strong>Questions Answered<\/strong><\/p>\n<ul>\n<li>How large is China\u2019s drug-treatable ovarian cancer population, and how will drug-treatment rates change during the forecast period?<\/li>\n<li>Which are the most commercially relevant drugs in China\u2019s ovarian cancer market and why? What are interviewed experts\u2019 insights into current treatment options?<\/li>\n<li>What are the market access considerations for key therapies in the ovarian cancer pipeline in China? What sales could they secure in ovarian cancer? What are interviewed experts\u2019 opinions of these therapies?<\/li>\n<li>What are the key drivers of and constraints in China\u2019s ovarian cancer therapy market, and how will the market evolve over the forecast period?<\/li>\n<\/ul>\n<p><strong>Content Highlights<\/strong><\/p>\n<p>Geographies: China.<\/p>\n<p>Primary research: Country-specific qualitative and quantitative insights driven by 5 thought-leader interviews and 75 surveys with medical oncologists. Supported by survey data collected for this and other Clarivate research.<\/p>\n<p>Epidemiology: Diagnosed prevalence of ovarian cancer in urban versus rural China. Clinically and market-relevant drug-treatable populations.<\/p>\n<p>Forecast: 10-year, annualized, drug-level sales and patient share of key ovarian cancer regimens through 2031, based on primary and secondary market research to formulate bottom-up assumptions.<\/p>\n<p>Emerging therapies: Phase III\/PR: > 10 drugs; Phase II: 10 drugs; Phase I\/II: 7; coverage of select Phase I products.<\/p>\n<p><strong>Product Description <\/strong><\/p>\n<p><em>China In-Depth\u00a0<\/em>offers comprehensive market intelligence, includingworld-class epidemiology, keen insight into the China-specific A&#038;R environment, current treatment paradigms, in-depth pipeline assessments,and drug forecasts supported by detailed primary and secondary research.This solution helps companies gauge commercial outlooks and optimizeclinical development, subpopulation targeting, physician messaging, andoverall long-term strategy in China.<\/p>\n","protected":false},"template":"","class_list":["post-389773","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-ovarian-cancer","biopharma-product-china-in-depth","biopharma-geography-china","biopharma-date-960"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/389773","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":2,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/389773\/revisions"}],"predecessor-version":[{"id":576205,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/389773\/revisions\/576205"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=389773"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}